Compare Revvity Inc (RVTY) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Banco Santander SA — how do they compare? Revvity Inc trades at $124.14 (market cap $13.82B), while Banco Santander SA trades at $14.69 (market cap $214.37B). The key difference: Banco Santander SA is far larger — about 15.5× Revvity Inc's market cap, and Banco Santander SA pays the higher dividend (1.9%). Which is the better fit depends on your goals.
| RVTY | SAN | |
|---|---|---|
Market Cap | $13.82B | $214.37B |
Sector | Technology | Financials |
52-Week High | $130.94 | $15.05 |
52-Week Low | $82.26 | $9.65 |
Enterprise Value | $16.14B | — |
Dividend Yield | 0.23% | 1.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% over 24 hours, with a bullish technical signal driven by moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, supported by diagnostics growth and improved cash flow. Recent news includes the acquisition of Human Cell Design and product launches, indicating strategic expansion.
Outlook remains positive with a consensus price target of $136.20, offering ~7% upside, but high P/E of 59.54 poses valuation risk. Key opportunities include earnings momentum and innovation; risks involve premium valuation and competitive pressures in the healthcare sector.
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal supported by moving averages. The stock shows a P/E of 14.47 and a net income margin of 26.25%, with Q1 2026 earnings beating expectations but Q2 missing. Recent news highlights the completion of the Webster acquisition, expanding U.S. presence and diversifying the banking franchise.
Outlook is positive with analyst consensus at 'Moderate Buy' (64% buy ratings), though risks include volatile cash flows and high debt levels. Revenue growth is steady, but negative operating cash flow in 2024-2025 warrants monitoring. The stock offers value with solid profitability, but investors should weigh acquisition integration risks against expansion benefits.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
